Reduced status of plasma total antioxidant capacity in schizophrenia

被引:141
作者
Yao, JK
Reddy, R
McElhinny, LG
van Kammen, DP
机构
[1] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15206 USA
[2] Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA 15213 USA
关键词
antioxidant defense system; total antioxidant status; haloperidol;
D O I
10.1016/S0920-9964(98)00030-9
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
To examine whether antioxidant capacity is reduced in patients with schizophrenia, we determined plasma total antioxidant status (TAS) by quenching the absorbance of the radical cation formed by the reaction of 2,2'-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid) with a metmyoglobin and hydrogen peroxide. TAS serves as an index of net antioxidant activity derived from various antioxidants in plasma. Male schizophrenic patients were compared with age- and sex-matched healthy control subjects, using a within-subject, repeated measures, on-off-on haloperidol treatment design. Drug-free patients were free of all psychotropic medications for an average of 32 days. Plasma TAS was significantly lower in patients with schizophrenia than in normal controls. Plasma TAS in patients was significantly and inversely correlated with symptom severity during the drug-free condition. There were no significant differences between on and off haloperidol-treatment conditions. When patients returned to haloperidol treatment after relapse, the plasma TAS remained fairly constant and was not significantly different from the same individuals during haloperidol-stabilization or drug-free periods. These findings are indicative of an impaired antioxidant defense system, not attributable to neuroleptic treatment, and lend further support to the notion that oxidative stress may have a pathophysiological role in schizophrenia. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 32 条
[1]  
ABDALLA DSP, 1986, CLIN CHEM, V32, P805
[2]  
BECKER K, 1994, INT J VITAM NUTR RES, V64, P306
[3]  
BUNNEY WE, 1963, ARCH GEN PSYCHIAT, V9, P280
[4]  
CHOW KC, 1992, VITAMIN E HLTH DIS, P683
[5]   BLOOD COTININE LEVELS AS INDICATORS OF SMOKING TREATMENT OUTCOME [J].
HALL, SM ;
HERNING, RI ;
JONES, RT ;
BENOWITZ, NL ;
JACOB, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 35 (06) :810-814
[6]   THE ANTIOXIDANTS OF HUMAN EXTRACELLULAR FLUIDS [J].
HALLIWELL, B ;
GUTTERIDGE, JMC .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1990, 280 (01) :1-8
[7]   THE INTEGRATED ANTIOXIDANT SYSTEM [J].
JACOB, RA .
NUTRITION RESEARCH, 1995, 15 (05) :755-766
[8]   COMPARISON OF TESTS USED TO DISTINGUISH SMOKERS FROM NONSMOKERS [J].
JARVIS, MJ ;
TUNSTALLPEDOE, H ;
FEYERABEND, C ;
VESEY, C ;
SALOOJEE, Y .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1987, 77 (11) :1435-1438
[9]  
KOVALEVA ES, 1989, ZH NEVROPATOL PSIKH, V89, P108
[10]  
Lamont J, 1997, CLIN CHEM, V43, P852